Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2024-07-17 EDT			5-day change	1st Jan Change
919 ^DKK	-5.26%		-5.86%	+31.64%

07-17	Health Care Climbs as J&J Rallies - Health Care Roundup	DJ
07-17	European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	MT

NOVO NORDISK : Receives a Sell rating from UBS

January 09, 2023 at 05:39 am

Michael Leuchten from UBS retains his negative opinion on the stock with a Sell rating. The target price has been modified and is now set at DKK 680 compared to DKK 700.

Latest news about Novo Nordisk A/S

Health Care Climbs as J&J Rallies - Health Care Roundup	07-17	DJ
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	07-17	MT
Novo Nordisk to Update Weight Loss Drugs Labels Over EMA's Safety Recommendation	07-17	MT
European shares slide as tech stocks weigh	07-17	RE
Dutch government should not subsidise weight-loss drug Wegovy, adviser says	07-17	RE
Roche reports positive early results in obesity drug trial	07-17	RE
Dutch Health Care Wary of Reimbursing Novo Nordisk's Obesity Drug Cost	07-17	MT
Novo Nordisk's Main Owner Leads $100 Million Financing of Biotech Firm Asceneuron	07-16	DJ
Novo owner backs Swiss biotech Asceneuron in $100 million round	07-16	RE
Health Care Declines on Regulatory Fears - Health Care Roundup	07-15	DJ
European Equities Close Lower in Monday Trading; Luxury Goods Stocks Fall as Burberry Reports 'Disappointing' Q1 Results, Fires CEO	07-15	MT
Novo Nordisk Says No Meeting Scheduled With US Senate Aides, Senior Executives	07-15	MT
Novo Nordisk Reported to Meet Senate Staff Over Decision to Discontinue Levemir Insulin	07-15	MT
Novo Nordisk Denies Reported Meeting with US Senate Aides Over Insulin Discontinuation	07-15	MT
Novo Nordisk to Meet US Senate Aides Over Levemir Insulin Sales Halt	07-15	MT
Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market	07-12	RE
Ozempic linked with lower dementia risk, nicotine use, British study finds	07-12	RE
European Equities Close Higher in Friday Trading; Unilever to Cut 3,200 European Jobs	07-12	MT
EU Drug Regulator Issues New Safety Measures for GLP-1 Drugs Amid Aspiration Risk Concerns	07-12	MT
Patients on weight-loss drugs should inform doctor before surgery, EU regulator says	07-12	RE
Novo Nordisk's Ozempic Reduces Dementia and Cognitive Risks, Oxford Study Says	07-12	MT
NOVO NORDISK : Buy rating from Deutsche Bank	07-12	ZD
Health Care Up as Obesity-Drug Wars Continue -- Health Care Roundup	07-11	DJ
European Equities Close Higher Thursday; UK GDP Grows More Than Expected	07-11	MT
Global markets live: Tesla, Citigroup, BP, Novo Nordisk, JPMorgan...	07-11

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Sector

Pharmaceuticals

Calendar

2024-08-07 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Novo Nordisk CEO: Demand for Wegovy outstrips supply

May 02, 2024 at 12:36 pm

NOVO NORDISK : Q1 beat; guidance upgrade but sentiment nonetheless dampened by price reductions

May 02, 2024 at 12:09 pm

Novo Nordisk doesn't disappoint

January 31, 2024 at 10:48 am

More Strategies

Ratings for Novo Nordisk A/S

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

919 DKK

Average target price

956.8 DKK

Spread / Average Target

+4.11%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVO NORDISK A/S	+31.64%	597B
ELI LILLY AND COMPANY	+55.35%	815B
JOHNSON & JOHNSON	-0.10%	377B
MERCK & CO., INC.	+15.47%	319B
ABBVIE INC.	+13.10%	310B
ASTRAZENECA PLC	+15.51%	247B
NOVARTIS AG	+16.72%	228B
AMGEN INC.	+16.54%	180B
PFIZER, INC.	+4.31%	170B
SANOFI	+2.52%	126B

Other Pharmaceuticals

Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

NOVO NORDISK : Receives a Sell rating from UBS

Latest news about Novo Nordisk A/S

Chart Novo Nordisk A/S

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Novo Nordisk A/S

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals